cenvacibart

An immunoglobulin G4 (igG4), human anti-factor XI (FXI) antibody, with potential anti-thrombotic activity. Upon administration, cenvacibart targets and binds to the catalytic domain of FXI, thereby preventing the activation of FXI (FXIa). The abrogation of FXI activation prolongs the activated partial thromboplastin time (aPTT) and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization.